| Autor: |
Trotman, Judith Buske, Christian Tedeschi, Alessandra and Matous, Jeffrey V. MacDonald, David Tam, Constantine S. and Tournilhac, Olivier Ma, Shuo Treon, Steven P. Oriol, Albert and Ping, Jerry Briso, Eva M. Arango-Hisijara, Israel and Dimopoulos, Meletios A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
Purpose: The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenstrom macroglobulinemia. Results from the final analysis are now reported. Patients and Methods: Ibrutinib 420 mg was administered once daily to patients (N = 31) who failed to achieve at least a minor response (MR) or who relapsed = partial response) rates increasing from 61% at 6 months to 77% at 60 months. Median OS was not reached. Seventeen of 21 patients (81%) with baseline hemoglobin |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
